Clinical development of candidate HIV vaccines: Different problems for different vaccines

AIDS Research and Human Retroviruses

Volumn 30, Issue 4, 2014, Pages 325-329

  Shapiro, Stuart Z ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNITY; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; REVIEW; STANDARD; VIRAL CLEARANCE; VIREMIA; VIRUS DETECTION; VIRUS LOAD;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HIV; HIV INFECTIONS; HUMANS;

EID: 84897836071     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0114     Document Type: Review

References (18)

1. Fruth U: Considerations regarding efficacy endpoints in HIV vaccine trials: Executive summary and recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in support of the Global HIV Vaccine Enterprise. Vaccine 2009;27:1989-1996.
2. Yang H, Wu H, Hancock G, et al.: Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis 2012;206:552-561.
3. Saag M: When to start: As soon as possible. J Int AIDS Soc 2012;15(Suppl 4):18070.
4. Archin NM, Vaidya NK, Kuruc JD, et al.: Immediate antiviral therapy appears to restrict resting CD4 + cell HIV-1 infection without accelerating the decay of latent infections. Proc Natl Acad Sci USA 2012;109:9523-9528.
5. Walker BD and Hirsch MD: Antiretroviral therapy in early HIV infection. N Engl J Med 2013;368:279-281.
6. Powers KA, Ghani AC, Miller WC, et al.: The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: A modeling study. Lancet 2011;378:256-268.
7. Blankson JN: Control of HIV-1 replication in elite suppressors. Discov Med 2010;9:261-266.
8. Walker BD: Elite control of HIV infection: Implications for vaccines and treatments. Top HIV Med 2007;15:134-136.
9. Sharp DS and Gahlinger PM: Regression analysis in biological research: Sample size and statistical power. Med Sci Sports Exerc 1988;20:605-610. (Pubitemid 19018300)
10. Hansen SG, Ford JC, Lewis MS, et al.: Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011;473:523-527.
11. Walker BD and Burton DR: Toward an AIDS vaccine. Science 2008;320:760-764. (Pubitemid 351929619)
12. Shapiro SZ: HIV vaccine development: Strategies for preclinical and clinical investigations. AIDS Res Hum Retroviruses 2013;29:1401-1406.
13. Shiver JW, Fu T-M, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiencyvirus immunity. Nature 2002;415:331-335. (Pubitemid 34087555)
14. Wilson NA, Reed J, Napoe GS, et al.: Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006;80:5875-5885. (Pubitemid 43849165)
15. Liu J, O'Brien KL, Lynch DM, et al.: Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009;457:87-91.
16. Watkins DI: The hope for an HIV vaccine based on induction of CD8+ T lymphocytes-A review. Mem Inst Oswaldo Cruz 2008;103:119-129. (Pubitemid 351535005)
17. Freel SA, Saunders KO, and Tomaras GD: CD8 + T-cellmediated control of HIV-1 and SIV infection. Immunol Res 2011;49:135-146.
18. Katsikis PD, Mueller YM, and Villinger F: The cytokine network of acute HIV infection: A promising target for vaccines and therapy to reduce viral set-point PLoS Pathol 2011;7(8):e1002055.